Skip to main content
Clinical Trials/NCT05433220
NCT05433220
Recruiting
Not Applicable

PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure (PROMPT-HF) at Inova

Inova Health Care Services1 site in 1 country5,000 target enrollmentAugust 25, 2022
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Inova Health Care Services
Enrollment
5000
Locations
1
Primary Endpoint
Increased use of GDMT in patients with Heart Failure with Reduced Ejection Fraction
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

A randomized, single-blind intervention trial to test the comparative effectiveness of an electronic health record best practice advisory system that informs clinicians of guideline-indicated and FDA-approved heart failure medications currently not prescribed to their patients with heart failure versus usual care (no alert and how things are done currently). The purpose of the alert is to stimulate appropriate medication prescription for patients with heart failure and a reduced ejection fraction. This will be done across outpatient Inova clinics and at the five Inova hospitals.

Registry
clinicaltrials.gov
Start Date
August 25, 2022
End Date
August 1, 2026
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age\>18 Years
  • Seen by a Cardiologist in an Inova clinic or Inova hospital setting
  • Left Ventricular Ejection Fraction ≤40%

Exclusion Criteria

  • Opted out of EHR-based research
  • Hospice care
  • Already receiving maximally titrated doses of each of the four classes of evidence- based HFrEF medical therapy
  • Prior heart transplant

Outcomes

Primary Outcomes

Increased use of GDMT in patients with Heart Failure with Reduced Ejection Fraction

Time Frame: 30 days after randomization

The primary outcome for the trial will be the proportion of patients with HFrEF who have an increase in the number of prescribed evidence-based therapies for HFrEF (beta-blockers, ACE-I/ARB/ARNI, MRA, SGLT2i) 30 days after randomization.

Secondary Outcomes

  • All-cause hospitalization and all-cause mortality at 30 days(30 days)
  • All-cause hospitalization and all-cause mortality at 90 days(90 days)
  • All-cause hospitalization and all-cause mortality at 180 days(180 days)
  • All-cause hospitalization and all-cause mortality at 1 year(1 year)

Study Sites (1)

Loading locations...

Similar Trials